Login to Your Account

Catalyst Files for $40M IPO To Advance Addiction Drug

By Karen Pihl-Carey

Thursday, July 27, 2006
A company formed in January 2002, based on research conducted at the Brookhaven National Laboratory, filed for an initial public offering to raise $40.25 million - money to support clinical development of its only product, a GABA analog to treat cocaine addiction. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription